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Complement factor H (FH) inhibits complement activation
and interacts with glomerular endothelium via its complement
control protein domains 19 and 20, which also recognize hepa-
ran sulfate (HS). Abnormalities in FH are associated with the
renal diseases atypical hemolytic uremic syndrome and dense
deposit disease and the ocular disease age-related macular
degeneration. Although FH systemically controls complement
activation, clinical phenotypes selectively manifest in kidneys
and eyes, suggesting the presence of tissue-specific determi-
nants of disease development. Recent results imply the impor-
tance of tissue-specifically expressed, sulfated glycosaminogly-
cans (GAGs), like HS, in determining FH binding to and activity
onhost tissues. Therefore, we investigatedwhichGAGsmediate
human FH and recombinant human FH complement control
proteins domains 19 and 20 (FH19–20) binding to mouse glo-
merular endothelial cells (mGEnCs) in ELISA. Furthermore, we
evaluated the functional defects of FH19–20 mutants during
complement activation by measuring C3b deposition on
mGEnCs using flow cytometry. FH and FH19–20 bound dose-
dependently to mGEnCs and TNF- treatment increased bind-
ing of both proteins, whereas heparinase digestion and compe-
tition with heparin/HS inhibited binding. Furthermore, 2-O-,
and 6-O-, but not N-desulfation of heparin, significantly
increased the inhibitory effect onFH19–20binding tomGEnCs.
Compared with wild type FH19–20, atypical hemolytic uremic
syndrome-associated mutants were less able to compete with
FH in normal human serum during complement activation on
mGEnCs, confirming their potential glomerular pathogenicity.
In conclusion, our study shows that FH and FH19–20 binding
to glomerular endothelial cells is differentially mediated by
HS but not other GAGs. Furthermore, we describe a novel,
patient serum-independent competition assay for pathogenicity
screening of FH19–20 mutants.
The complement system, which consists of the classical, lec-
tin, and alternative pathway, initiates and amplifies inflamma-
tory responses, including proliferative glomerulonephritis
(1–3). The three pathways converge in the activation of com-
plement componentC3 and lead to the formation ofmembrane
attack complexes that lyse the affected cells. The alternative
pathway is initiated by spontaneous hydrolysis of C3 (4), even-
tually leading to covalent attachment of C3b to both adjacent
host and non-host cell surfaces (5) and the release of the proin-
flammatory anaphylatoxin C3a (6). Deposited C3b binds com-
plement factor B and, after proteolytic cleavage by factor D,
forms C3 convertases (C3bBb) on the cell surface, providing
localized feed-forward amplification of complement activation
(7). To protect host cells from complement-mediated damage,
several regulatory proteins disrupt the complement cascade,
including the plasma proteins complement factor H (FH)2
and FH-like protein 1, and membrane-bound regulators like
complement receptor 1 (CD35), membrane cofactor protein
(CD46), and decay accelerating factor (CD55) (8–12).
FH, a 155-kDa glycoprotein, is the major inhibitor of the
alternative pathway both in the fluid phase and on cellular sur-
faces (13–15). It competes with factor B for C3b (16), acts as a
cofactor for complement factor I-mediated proteolytic inacti-
vation of C3b (14), and promotes the dissociation of C3bBb
convertases (17). FH consists of 20 complement control protein
(CCP, also called short consensus repeats) domains of 60
amino acids each (18). The N-terminal domains CCP1–4 con-
tain the cofactor and decay accelerating activity (19, 20),
whereas CCP7 andCCP19–20mediate cell surface recognition
by binding to sulfated glycosaminoglycans (GAGs) on host cells
(21–23). Mutations in the two C-terminal surface recognition
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domains can result in the rare renal disease atypical hemolytic
uremic syndrome (aHUS) (24). Furthermore, a polymorphism
in CCP7 (Y402H) has been associated with the ocular disease
age-related macular degeneration (AMD) as well as the rare
renal disease dense deposit disease (DDD) (25). In turn, the rare
SCR20 mutation R1210C is associated with both AMD and
aHUS (26). Interestingly, mutations cluster within the cell sur-
face recognition domains, and whereas FH systemically con-
trols complement activation, complement-mediated damage
appears restricted to eyes and kidneys.
Recent studies (21) provide evidence that the tissue-specific
diseasemanifestation is mediated by the differential expression
of heparan sulfates (HS), a class of GAGs. HS are linear, nega-
tively charged polysaccharides that can be extensivelymodified
by sulfation and epimerization to yield highly heterogeneous
structures (27). The exact sequence of modifications along the
carbohydrate backbone, the “HS code,” generates specifically
sulfated domains that are recognized by proteins with the cor-
responding HS binding site. This way, endothelial HS plays a
crucial role during inflammation by binding to selectins, integ-
rins, chemokines, cytokines, inflammatory cells, and comple-
ment proteins (28–32). Clark et al. (21) recently found that
HS-mediated FH binding in the glomerulus is primarily medi-
ated by CCP19–20, providing an explanation for the C-termi-
nal localization of aHUS-related FH mutations. Their observa-
tions are supported by earlier evidence from FH knock-out
mouse models. FH-deficient mice display a phenotype reflect-
ing humanDDD,which is associatedwith systemic loss of com-
plement control in the fluid phase (33). Recently, themodel has
been refined to a hepatocyte-specific FH knock-out, which
results in a phenotype even closer to human C3 glomerulone-
phropathies that include DDD (34). However, if mice instead
express a FH construct lacking the five C-terminal CCPs, the
resulting phenotype reflects aHUS, with glomerulospecific,
complement-mediated damage despite normal plasma C3 con-
centrations (35). The strong similarities between human and
murine disease phenotypes led us to investigate the genotype-
phenotype relation of FH19–20 mutants in the context of
mouse glomerular endothelial cells.
In a previous study we showed that aHUS-associated FH
CCP19–20 (FH19–20) mutants exhibit impaired binding to
C3b/C3d and impaired or enhanced binding to mouse glomer-
ular endothelial cells (mGEnCs) and heparin (36). Our current
study aimed to determine the functional effects of FH19–20
mutations and evaluate the role of GAGs in binding of FH to
glomerular endothelium, the clinically affected tissue.Wedem-
onstrated that binding of FH to mGEnCs is partially mediated
by HS, but not chondroitin sulfate, dermatan sulfate or hyal-
uronan. Furthermore, several aHUS-associated FH19–20
mutants were less able to compete with full-length FH com-
pared with wild type FH19–20 during alternative pathway
activation on mGEnCs. The obtained results not only confirm
the evaluatedmutants’ potential role in aHUS etiology but illus-
trate glomerular pathogenicity screening of FH mutants under
highly controlled experimental conditions without requiring
access to patient serum.
Experimental Procedures
FH, FH19–20 Mutants, and GAG Preparations—Factor H
(FH, Tyr-402 homozygous) was isolated fromhealthy donors as
described (37). Recombinant wild type FH19–20 and aHUS-
associated FH19–20 mutants (D1119G, W1183L, T1184R,
E1198A, R1210A, R1215Q) (38) were generated and purified as
described (39). GAG preparations included heparin, HS from
bovine kidney, hyaluronic acid (Sigma), 2-O-desulfated hepa-
rin, 6-O-desulfated heparin, and N-desulfated heparin (Neo-
parin Inc., Alameda, CA).
Cell Culture—Conditionally immortalized mGEnCs with all
features of primary glomerular endothelial cells were cultured
as described (40).Where indicated, cells were activated by incu-
bation with tumor necrosis factor (TNF)- (10 ng/ml; Pepro-
tech, Rocky Hill, NJ) for 18 h.
Binding of FH and FH19–20 to Mouse Glomerular Endothe-
lial Cells in Enzyme-linked Immunosorbent Assays (ELISAs)—
mGEnCs were grown in 96-well plates (Corning Life Sciences,
Schiphol-Rijk, The Netherlands). The cells were washed with
phosphate-buffered saline (PBS) and incubatedwith serial dilu-
tions of FH and FH19–20 (0–80 g/ml) in PBS containing 2%
bovine serum albumin (2% PBA, w/v; Sigma) for 2 h at 37 °C.
Binding was detected using polyclonal rabbit anti-human FH
antiserum (a kind gift from Dr. J. Hellwage, Hans Knöll Insti-
tute, Jena, Germany). The cells were then washed twice with
0.05% Tween 20 in PBS (PBS/Tween; v/v) and subsequently
incubated with horseradish peroxidase-conjugated F(ab)2
donkey anti-rabbit IgG (Jackson ImmunoResearch Laborato-
ries, Inc.,West Grove, PA) in 2% PBA 1 h at room temperature.
Finally, the cells were washed three times with PBS/Tween and
incubated with tetramethylbenzidine substrate solution (Bio-
Rad). The reaction was stopped after 15 min with an equal vol-
ume of 2 MH2SO4, and the absorbance at 450 nmwasmeasured
using a Bio-Rad Multiplate Reader (Bio-Rad). Full-length FH
and wild type FH19–20 were used at their 50% effective con-
centrations (EC50) for the remaining binding assays.
Effect of GAG-degrading Enzyme Treatment and (Modified)
Heparin/HS Competition on FH/FH19–20 Binding to
mGEnCs—HS on TNF--activated mGEnCs was removed by
treatment with 0.25 units/ml heparinase I, II, and III (Sigma) in
0.1 M sodium acetate, 0.2 mM calcium acetate (pH 7.0) for 1 h at
37 °C. Cell surfaceHSdegradationwas confirmed bymeasuring
the expression of the HS epitope recognized by the antibody
AO4B08 (41). Chondroitin sulfate/dermatan sulfate was re-
moved by treating mGEnCs with 1 units/ml chondroitinase
ABC (Sigma) in 25mMTris/HCl, 2mMmagnesium acetate (pH
8.0) for 1 h at 37 °C. The activity of chondroitinase ABC was
checked with the anti-chondroitin sulfate antibody IO3H10
(42). Hyaluronic acid was removed by 0.1% hyaluronidase (w/v;
from bovine testes, type I-S; Sigma) in 0.1 M sodium acetate (pH
6.0) for 1 h at 37 °C, and its activity was confirmed using bioti-
nylated hyaluronic acid-binding protein (Sigma). For the com-
petition assays, FH/FH19–20 were preincubated with the dif-
ferent GAG preparations or the modified heparinoids (50
g/ml) before being added to the cells. Binding of FH/FH19–20
was then determined using ELISA as described.
Factor HMutations Impair Activity on Glomerular Endothelium
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Alternative Pathway Activation on mGEnCs and FH19–20
(Mutant) Competition—TNF--activated mGEnCs were
grown in 48-well plates (Corning Life Sciences). After washing
twice with PBS, the cells were incubated with 20% pooled nor-
mal human serum (NHS; Complement Technology, Inc., Tyler,
TX) in veronal-buffered saline (15mM veronal, 145mMNaCl, 3
mM MgCl2, 5 mM EGTA, 0.025% NaN3 (pH 7.3)) at 37 °C.
Twenty percent heat-inactivated NHS (30 min at 56 °C) in
veronal-buffered saline was used as the negative control. Con-
vertase formation was stopped after 60min by adding EDTA to
a final concentration of 10mM. The cells were then detached by
vigorous pipetting, washed with 0.5% PBA, and incubated with
rabbit anti-human C3/C3b (1 g/ml; clone H-300; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) in 0.5% PBA for 30 min at
4 °C. After washing and incubating with a goat anti-rabbit IgG:
Alexa488 (Life Technologies) for 30min at 4 °C, C3b deposition
onmGEnCswas detected using a BeckmanCoulter FC500 flow
cytometer and evaluated using CXP2.2 software. To evaluate
the functional effects of aHUS-associated mutations, 10 g/ml
wild type or mutant FH19–20 were added to NHS to compete
with full-length FH during the activation step.
Statistical Analysis—Titration data were fitted using non-
linear regression with a “log(agonist) versus response” model
using GraphPad Prism version 5.03 (GraphPad Software Inc.,
San Diego, CA). Values are expressed as the means S.E., and
significance was evaluated by Student’s t test or analysis of vari-
ance using GraphPad Prism. Post hoc comparison of individual
means was performed using Tukey’s method. Binding experi-
ments were performed four times in duplicate. Results of the
activity assays represent data from three separate experiments.
Results
TNF- Treatment Increases Full-length FH and FH19–20
Binding to Glomerular Endothelial Cells—Complement FH
binds endothelial cells (43), and recently, we demonstrated the
differential binding of FH19–20 and FH19–20 mutants to
mGEnCs (36). In the current studywe investigated the ability of
mGEnCs to bind FH and FH19–20 using ELISA and found that
both FH and FH19–20 exhibited specific and dose-dependent
binding to mGEnCs (Fig. 1a). Activation of mGEnCs with
TNF- to simulate the inflammatory conditions of aHUS
significantly increased binding of both full-length FH and
FH19–20 1.5-fold and 1.3-fold, respectively (Fig. 1b). To
take advantage of the observed increase in signal, we investi-
gated binding of FH and FH19–20 using TNF--activated
mGEnCs for the subsequent experiments.
Binding of Full-length FHand FH19–20 toGlomerular Endo-
thelial Cells Is DifferentiallyMediated byHS but Not Chondroi-
tin Sulfate or Dermatan Sulfate—Because endothelial glycoca-
lyx composition and modifications differ between different
tissues, we investigated the role of different types of GAGs in
regulating binding of FH and FH19–20 to glomerular endothe-
lium. Therefore, mGEnCs were either treated with amixture of
glycosidases to degrade specific GAGs before measuring FH
and FH19–20 binding, or the proteins were preincubated with
soluble GAGs to compete for cell surface GAGs on mGEnCs.
Although removal of chondroitin sulfate using chondroitinase
ABC (CSase ABC) had no effect on binding of either full-length
FH (Fig. 2a) or FH19–20 (Fig. 2b), digestingHSwith heparinase
I, II, and III (HepI-II-III) significantly reduced binding 1.7-
fold and 1.2-fold, respectively. Treatment with hyaluroni-
dase, which removes hyaluronic acid, decreased binding of
FH19–20 toTNF--activatedmGEnCs, whereas the binding of
full-length FH was unaffected. However, binding of both pro-
teins was significantly decreased after treating mGEnCs with
both hyaluronidase and HepI-II-III, although not below the
observed effect of HepI-II-III treatment alone. Accordingly,
soluble hyaluronic acid did not effectively compete with
mGEnC-associated hyaluronic acid for full-length FH and
FH19–20 (Fig. 3). In contrast, preincubation with heparin or
HS significantly inhibited the binding of full-length FH and
FH19–20 to TNF--activated mGEnCs.
Because the interaction between HS and FH depends on the
sulfation of the GAG backbone, we evaluated the effect of sev-
eral selectively desulfated heparinoids in competition with HS
in the glomerular endothelial glycocalyx. None of the modified
heparinoids affected the binding of full-length FH when com-
pared with heparin as the competitor (Fig. 3a). In contrast, pre-
incubation with 2-O- and 6-O-desulfated heparin significantly
FIGURE 1. Full-length FH and FH19–20 bind differentially to mGEnCs. a,
serial dilutions of FH and recombinant FH CCP19–20 (FH19–20) were added
to mGEnCs, and binding was detected using ELISA. Full-length FH bound
mGEnCs at a lower EC50 concentration than FH19–20, suggesting the pres-
ence of additional binding sites for ligands on the cell surface. b, TNF- acti-
vation of mGEnCs resulted in an increased binding of full-length FH and
FH19–20. The results were normalized on binding of the complement factors
to untreated mGEnCs. **, p 0.01 versus untreated mGEnCs; ***, p 0.001
versus untreated mGEnCs.
Factor HMutations Impair Activity on Glomerular Endothelium
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reduced the binding of FH19–20 to mGEnCs compared with
heparin (Fig. 3b), indicating that these modifications could be
involved in the self-recognition of glomerular endothelium by
FH19–20. N-Desulfated heparin in turn did not affect binding
of FH19–20 to mGEnCs. Thus, 2-O- and 6-O-desulfated hep-
arin showed differential inhibitory effects on the binding of full-
length FH and FH19–20 to mGEnCs. Finally, GAG digestion
appeared more effective in reducing full-length FH binding
compared with FH19–20 (Fig. 2), whereas the opposite was
observed during the competition experiments (Fig. 3).
aHUS-associated FH19–20 Mutants Are Less Able to Com-
pete with Full-length FH for Ligands on mGEnCs Compared
with Wild Type FH19–20 during Alternative Pathway
Activation—We previously identified three types of defects
caused by mutations in FH19–20, i.e. decreased binding to
C3b/C3d and decreased or increased binding to heparin and
mGEnCs (36). However, the functional consequences of these
mutations for complement control on glomerular endothelium
were still unexplored. For the current study we selected FH
mutants to include all defined defects as well as their combina-
tions and evaluated their ability to compete with full-length FH
on mGEnCs during alternative pathway activation.
Incubating mGEnCs with normal human serum resulted in
significant C3b deposition on the cell surface compared with
heat-inactivated human serum as measured in flow cytometry
(Fig. 4a). Competing with full-length FH for ligands on
mGEnCs using wild type FH19–20 further increased the
observed C3b deposition by1.7-fold, suggesting an increased
susceptibility to alternative pathway activation. Interestingly,
several of the screened aHUS-associated FH19–20 mutants
show a decreased ability to compete with full-length FH com-
pared with wild type FH19–20 (Fig. 4b). The effect is statisti-
FIGURE 2. Heparinase treatment reduces the binding of full-length FH
and FH19–20 to mGEnCs. Monolayers of TNF--activated mGEnCs were
treatedwith chondroitinase ABC (CSase ABC), amixture of heparinase I, II, and
III (HepI-II-III), hyaluronidase (HAase), or a combination of hyaluronidase
and heparinase I, II, and III (HAase-HepI-II-III). The binding of full-length FH (a)
and FH19–20 (b, both at EC50 concentrations) was measured by ELISA. The
results were normalized on binding of full-length FH and FH19–20 to
untreated mGEnCs. *, p 0.05 versus untreated mGEnCs; **, p 0.01 versus
untreatedmGEnCs; ***, p 0.001 versus untreatedmGEnCs; ****, p 0.0001
versus untreated mGEnCs.
FIGURE 3. Competition with soluble heparin and HS reduces the binding
of full-length FH and FH19–20 tomGEnCs. FH and FH19–20were preincu-
bated with 50 g/ml hyaluronic acid, HS, heparin, or 2-O-, 6-O-, and N-desul-
fated (desulf.) heparin before adding the mixtures to monolayers of TNF--
activated mGEnCs. The binding of full-length FH (a) and FH19–20 (b) to the
cells was then evaluated by ELISA. Preincubation with heparin and HS signif-
icantly reduced binding of both proteins, whereas 2-O- and 6-O-desulfation
selectively increased the inhibitory effect compared with heparin on
FH19–20 but not FH binding to mGEnCs. The results were normalized on
binding of full-length FH and FH19–20 tomGEnCs in the absence of compet-
itors (Untreated). *, p  0.05 versus untreated; **, p  0.01 versus untreated;
***, p 0.001 versus untreated; &, p 0.05 versus heparin; &&, p 0.01 versus
heparin.
Factor HMutations Impair Activity on Glomerular Endothelium
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cally significant for the mutants W1183L, E1198A, and
R1215Q, which appear unable to compete with full-length FH
at all, indicating a complete loss of function of the C-terminal
cell-surface recognition domains. Although the remaining
mutants, D1119G, T1184R, and R1210A, are not significantly
less able to compete with full-length FH compared with wild
type FH19–20, they all display a trend toward decreased
function.
Discussion
Previous in vitro studies on the interaction between FH and
endothelium or the effects of FH mutations on cell-surface
complement control used non-renal endothelial cells, which
might lack tissue-specific disease-determining factors. There-
fore, we characterized the GAG ligands for full-length FH and
FH19–20 on glomerular endothelial cells. Furthermore, we
explored the effect of aHUS-associated FH19–20mutations on
alternative pathway inhibition in the context of the physiolog-
ically affected tissue.
We found that both full-length complement FH and
FH19–20 bound dose-dependently tomGEnCs. TNF- activa-
tion of mGEnCs resulted in a significant increase in binding of
full-length FH and FH19–20 to the endothelial monolayer.
Thismight reflect a cellular response to provide additional pro-
tection fromcomplement-mediated damage during glomerular
inflammation. We previously showed that TNF- activation
increases the expression highly sulfated HS domains (recog-
nized by the antibodies AO4B08, EW3D10, and EW4G2) as
well as lowly sulfated HS (recognized by 10E4) (29). Total HS
expression in the endothelial glycocalyx increased 3-fold in
response to TNF-, which could result in an increased binding
of FH and FH19–20.
It is important to note that the interaction studies and path-
ogenicity screening of FH19–20mutantswere performedusing
murine instead of human glomerular endothelial cells. How-
ever, FH-deficient mouse and pig models suggest that the tis-
sue-specific determinants of FH-associated diseases are con-
served within mammals (33–35, 44). The animals develop a
DDD-like renal phenotype, and aged FH-deficient mice have
been used as the model for AMD (45). Furthermore, the DDD-
like phenotype converts to aHUS in FH-deficientmice express-
ing a transgenic FH variant lackingCCP16–20, as themodel for
FH mutants with C-terminal loss of function (35). The renal
disease phenotype can be reversed by injecting FH-deficient
mice with human FH, suggesting cross-reactivity between the
human and murine factors involved in complement regulation
(46).The removal of HS from the endothelial glycocalyx signif-
icantly reduced binding of both full-length FH and FH19–20,
confirming that HS mediates FH binding to glomerular endo-
FIGURE 4. aHUS-associated FH19–20 mutants are less able to compete with full-length FH during alternative pathway activation on mGEnCs. a,
TNF--activatedmGEnCswere incubatedwith 20%heat-inactivated andnormal human serum (NHS (h.i.) andNHS, respectively) andC3bdepositionon the cell
surface was evaluated using flow cytometry. b, adding 10 g/ml wild type FH19–20 (WT) to compete with FH for ligands in the cellular microenvironment
during alternative pathway activation significantly increases C3b deposition compared with incubation with NHS alone. Interestingly, several screened
FH19–20 mutants are less able to compete with full-length FH during activation, with the mutations W1183L, E1198A, and R1215Q resulting in an almost
complete loss of competitive ability. c, sequence alignment of mammalian FH CCP19–20 amino acid sequences. With the exception of D1119G, the loss of
inhibitory ability compared with wild type FH19–20 reflects the conservation of themutated amino acid in mammalian species (green, highly conserved; red,
not conserved). **, p 0.01 versusWT; ***, p 0.001 versusWT.MFI, mean fluorescence intensity.
Factor HMutations Impair Activity on Glomerular Endothelium
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theliumviaCCP19–20. In contrast, removal of chondroitin and
dermatan sulfate had no effect on the interaction between
mGEnCs and either of the proteins. Removal of hyaluronic acid
by hyaluronidase decreased binding of FH19–20, whereas the
addition of hyaluronic acid in soluble form had no effect on
binding. This apparent discrepancy could arise because hyalu-
ronidase treatment disturbs the integrity of the endothelial gly-
cocalyx, which includes GAGs and short branched N- and
O-linked oligosaccharides with negatively charged terminal
sialic acid residues (47).
In accordance with the GAG digestion results, competition
with soluble heparin and HS significantly diminished the inter-
action between mGEnCs and full-length FH or FH19–20.
Interestingly, 2-O- and 6-O-desulfated heparin significantly
decreased binding of FH19–20 to mGEnCs even further.
Although this effect is not observed for full-length FH, it could
be masked by the presence of additional non-HS ligands on
mGEnCs. These results suggest that FH19–20 preferentially
binds to heparan sulfate with low levels of 2-O- and 6-O-sulfa-
tion, contradicting previous observations that the interaction
between FH19–20 and heparin depends on high levels of sulfa-
tion (21). However, these experiments eithermeasured binding
of FH to heparin directly or competed with soluble heparinoids
for immobilized heparin. Our experiments in turn used modi-
fied heparins in solution to compete for HS in its physiological
environment, the endothelial glycocalyx. Therefore, 2-O- and
6-O-desulfated heparin could be more effective in competing
for the physiological HS ligands of FH19–20 compared with
unmodified heparin. Both in the GAG digestion and competi-
tion experiments, complete reduction of FH and FH19–20
binding could not be achieved, suggesting that other, non-GAG
ligands indeed contribute to the interaction between FH and
glomerular endothelium.As full-length FH is glycosylated, con-
trary to FH19–20, interactions between cell surface receptors
and glycans in FH could contribute to the interaction as well.
We previously characterized three different functional
defects of FH19–20 mutants, i.e. decreased ability to compete
with wild type FH19–20 for C3b/C3d (W1183L, T1184R, and
R1210A), decreased (R1210A and R1215Q), or increased
(T1184R and E1198A) binding to heparin and mGEnCs (Table
1) (36). Although we originally found none of these defects in
D1119G, later studies revealed a decreased affinity for C3b/C3d
(48). Because theD1119Gmutant still efficiently competeswith
wild type FH19–20 for C3b/C3d, themutationmight affect the
self-association characteristics of the two C-terminal CCPs,
preventing binding to C3b/C3d. Recently, the aHUS/AMD-as-
sociated R1210C mutation has been shown to introduce a gain
of function defect, as it enables the protein to form covalent
bonds with serum albumin (49, 50). The R1210A mutant used
in the current study lacks the surface-exposed cysteine; there-
fore, the observed effects can likely be attributed to a decrease
in electrostatic interactions with FH19–20 ligands.
However, the influence of these C-terminal FHmutations on
complement control on glomerular endothelium had not yet
been explored. Therefore, we designed a competition assay to
explore the effect of mutations in FH19–20 on glomerular
complement control. The alternative pathway activated spon-
taneously on mGEnCs as measured through a significant
increase in C3b deposition compared with heat-inactivated
serum. This represents an advantage of using mGEnCs com-
pared with human endothelium, which is protected from com-
plement attack from normal human serum. We observed sig-
nificant functional defects in three of the mutants, which are
likely caused by altered interactions with both complement
proteins and cell surface ligands.W1183Lhas a decreased affin-
ity for C3b/C3d and is apparently unable to compete with full-
length FH for the protein during complement activation.
E1198A shows an increased affinity for heparin and mGEnCs,
whereas binding of R1215Q to heparin is decreased. The loss of
a negatively and positively charged amino acid, respectively,
likely changes the specificity of the proteins for FH19–20 bind-
ing HS domains, leaving sufficient HS unoccupied to efficiently
inhibit complement activation onmGEnCs despite the compe-
tition. Note that competition using mutants with two of the
defined defects (T1184R and R1210A) did not have the largest
effect on alternative pathway inhibition on mGEnCs. Instead,
the observed decrease in competitive ability of the screened
FH19–20 mutants reflects the conservation of the affected
amino acid in mammalian species, with the exception of
D1119G (Fig. 4c). All other mutations in highly conserved
amino acids (W1183L, E1198A, and R1215Q) completely abol-
ish the protein’s ability to compete with full-length FH for
ligands on mGEnCs. However, additional FH19–20 mutants
will have to be screened to expand this observation.
Because recombinant proteins were used to evaluate the
functional effects of mutations in FH19–20, the experiments
can be performed without access to limited available aHUS
patient serum. Therefore, our assay is unaffected by variable
complement concentrations in patient sera, current disease
state, or improper handling of serum samples, as the same
human serum pool is used as a source of complement for all
FH19–20 mutants. However, potential pathogenic contribu-
tions of other serum factors, such as FH-like 1 and FH-related
proteins 1–5, will not be reflected in the obtained results.
In conclusion, this study is the first to demonstrate the role of
HS in binding of the full-length FH and FH19–20 to (TNF--
activated) glomerular endothelial cells. Furthermore, we
showed the pathogenic effect of several aHUS-associated
FH19–20 mutations on FH-mediated complement control on
the clinically affected tissue. Finally, we have described a com-
petition assay that enables pathogenicity screening of unchar-
acterized FH mutations without requiring access to limited
available patient serum.
TABLE 1
Functional characterization of aHUS-associated FH19–20mutants
Arrows indicate an increase (1), decrease (2), or no significant change (7) in
binding/activity.
FH19–20
mutant
C3b/C3d
binding
Heparin
binding
mGEnC
binding
Functional
activity
D1119Ga 7 7 7 7
W1183La 2 7 7 2
T1184R 2/7 1 1 7
E1198Aa 7 1 1 2
R1210A 2 2 2 7
R1215Qa 7 2 7 2
a Conserved amino acid; binding data adapted from Lehtinen et al. (36).
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